Researchers explore psilocybin as a potential alternative antidepressant for treatment-resistant depression, supported by "breakthrough therapy" status from the FDA.

Researchers are investigating psilocybin, found in "magic mushrooms," as a potential alternative antidepressant, especially for treatment-resistant depression. A clinical trial compares psilocybin to the SSRI escitalopram over six weeks. With over 300 million people globally affected by depression, and many not responding to standard treatments, psilocybin shows promise without some long-term side effects associated with current antidepressants. The FDA has granted it "breakthrough therapy" status.

October 22, 2024
8 Articles

Further Reading